Effectiveness of topiramate in lipomatosis comorbid with agoraphobia and migraine: Case study

0Citations
Citations of this article
20Readers
Mendeley users who have this article in their library.

Abstract

Topiramate has been used in epilepsy and migraine for more than ten years. Recently, it has gained importance in the treatment of obesity, particularly in combination with phentermine. We report the case of a 51-year-old woman suffering from agoraphobia with panic attacks, diabetes and migraine. In addition, she simultaneously developed generalized lipomatosis leading to a weight gain of more than 20[th]kg. She was given topiramate up to 100[th]mg per day in addition to an SSRI (citalopram) and a melatoninergic drug (agomelatine). Gradually, within two years after starting topiramate, she lost 20[th]kg, with a corresponding reduction of thorax and arm circumference. Although the mechanism of weight loss remains to be clarified, topiramate may be an alternative approach in patients suffering from generalized lipomatosis.

Cite

CITATION STYLE

APA

Koch, H. J. (2015). Effectiveness of topiramate in lipomatosis comorbid with agoraphobia and migraine: Case study. Archives of Psychiatry and Psychotherapy, 17(1), 5–8. https://doi.org/10.12740/APP/34715

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free